Praxis Precision Medicines Inc
NASDAQ:PRAX
Intrinsic Value
Praxis Precision Medicines, Inc. is a clinical-stage genetic neuroscience company that develops therapies for patients and families affected by complex and debilitating brain disorders. [ Read More ]
The intrinsic value of one
PRAX
stock under the Base Case scenario is
35.26
USD.
Compared to the current market price of 52.88 USD,
Praxis Precision Medicines Inc
is
Overvalued by 33%.
PRAX's market price has consistently been higher than its intrinsic value.This persistent overvaluation suggests the market may be overly optimistic about
PRAX or that its price is influenced by factors unrelated to fundamentals.
Praxis Precision Medicines Inc's market capitalization is 903.6m USD.
PRAX stock price is 52.88 USD.
PRAX stock (35.26 USD) is 33% less than its price (52.88 USD).
PRAX. Open DCF Valuation
PRAX stock (35.26 USD) is 33% less than its price (52.88 USD). Open Relative Valuation
PRAX has upside potential of 167% compared to the average analyst price target.
Open Wall St Estimates
PRAX's ROE (Return on Equity) has significantly decreased in the last 3 years from -33% to -169%, and is approaching profitability.
PRAX's ROIC (Return on Invested Capital) has significantly decreased in the last 3 years from -3 112% to -34 481%, and is approaching profitability.
PRAX has negative Operating Income for the last twelve months.
PRAX has negative Net Income for the last twelve months.
PRAX's ROE (Return on Equity) for the past 12 months is negative and is equal to -169%.
PRAX's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -34 481%.
PRAX's Revenue is forecast to grow at a rate of 224% per year over the next 3 years.
PRAX has negative Free Cash Flow for the last twelve months.
PRAX has negative three-year average ROE (Return on Equity): -98%. The company is not efficient at transforming stockholders' equity into net income.
PRAX has negative three-year average ROIC (Return on Invested Capital): -4 722%. The company is not efficient at using invested capital to generate operating income.
PRAX's short-term assets (85m USD) exceed its short-term liabilties (16m USD).
PRAX's long-term assets (88m USD) exceed its long-term liabilties (18m USD).
PRAX's D/E (Debt to Equity) is very low and is equal to 0.
PRAX's Altman Z-Score is very low and is equal to -2.79.
Valuation Backtest
Praxis Precision Medicines Inc
Run backtest to discover the historical profit from buying and selling
PRAX
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Praxis Precision Medicines Inc
Balance Sheet Decomposition
Praxis Precision Medicines Inc
| Current Assets | 84.9m |
| Cash & Short-Term Investments | 81.3m |
| Other Current Assets | 3.6m |
| Non-Current Assets | 3.1m |
| PP&E | 2.7m |
| Other Non-Current Assets | 416k |
| Current Liabilities | 15.7m |
| Accounts Payable | 5.8m |
| Accrued Liabilities | 8.5m |
| Other Current Liabilities | 1.4m |
| Non-Current Liabilities | 2.5m |
| Other Non-Current Liabilities | 2.5m |
Earnings Waterfall
Praxis Precision Medicines Inc
|
Revenue
|
2.4m
USD
|
|
Operating Expenses
|
-128.8m
USD
|
|
Operating Income
|
-126.4m
USD
|
|
Other Expenses
|
3.1m
USD
|
|
Net Income
|
-123.3m
USD
|
Free Cash Flow Analysis
Praxis Precision Medicines Inc
PRAX Profitability Score
Profitability Due Diligence
Praxis Precision Medicines Inc's profitability score is 19/100. The higher the profitability score, the more profitable the company is.
Score
Praxis Precision Medicines Inc's profitability score is 19/100. The higher the profitability score, the more profitable the company is.
PRAX Solvency Score
Solvency Due Diligence
Praxis Precision Medicines Inc's solvency score is 61/100. The higher the solvency score, the more solvent the company is.
Score
Praxis Precision Medicines Inc's solvency score is 61/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
PRAX Price Targets Summary
Praxis Precision Medicines Inc
According to Wall Street analysts, the average 1-year price target for
PRAX
is 141.37 USD
with a low forecast of 40.4 USD and a high forecast of 283.5 USD.
Ownership
PRAX Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
PRAX Price
Praxis Precision Medicines Inc
| Average Annual Return | -18.39% |
| Standard Deviation of Annual Returns | 98.7% |
| Max Drawdown | -99% |
| Market Capitalization | 903.6m USD |
| Shares Outstanding | 17 087 900 |
| Percentage of Shares Shorted | 3.27% |
Company Profile
Praxis Precision Medicines Inc
Country
Industry
Market Cap
Dividend Yield
Description
Praxis Precision Medicines, Inc. is a clinical-stage genetic neuroscience company that develops therapies for patients and families affected by complex and debilitating brain disorders. The company is headquartered in Boston, Massachusetts and currently employs 139 full-time employees. The company went IPO on 2020-10-16. The company is focused on translating genetic insights into the development of therapies for central nervous system (CNS) disorders. Its portfolio of CNS programs is structured by therapeutic focus in three primary franchises, which include Psychiatry, Movement Disorders, and Epilepsy. The company has three product candidates, which include PRAX-114, PRAX-944 and PRAX-562. PRAX-114 is an extra synaptic gamma-aminobutyric acid-A (GABAA) receptor preferring positive allosteric modulator (PAM) for the treatment of a range of patients suffering from major depressive disorder (MDD) and perimenopausal depression (PMD). PRAX-944 is a differentiated selective small molecule inhibitor of T-type calcium channels developed for the treatment of Essential Tremor (ET) and Parkinson's Disease(PD). PRAX-114 is developed for the treatment of a range of patients suffering from post-traumatic stress disorder (PTSD).
Contact
IPO
Employees
Officers
The intrinsic value of one
PRAX
stock under the Base Case scenario is
35.26
USD.
Compared to the current market price of 52.88 USD,
Praxis Precision Medicines Inc
is
Overvalued by 33%.
You don't have any saved screeners yet
